Recurrent and/or metastatic thyroid cancer: therapeutic options.
Thyroid cancer is relatively rare, accounting for 0.5 - 10 cases per 100,000 individuals per year. Despite their generally favourable prognosis, patients with differentiated thyroid cancer are at risk of tumour recurrence for decades after diagnosis. The optimal management remains controversial even...
Main Authors: | Karavitaki, N, Vlassopoulou, V, Tzanela, M, Tzavara, I, Thalassinos, N |
---|---|
Format: | Journal article |
Jezik: | English |
Izdano: |
2002
|
Podobne knjige/članki
-
Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy.
od: Karavitaki, N, et al.
Izdano: (2005) -
Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
od: Tzanela, M, et al.
Izdano: (2004) -
Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
od: Tzanela, M, et al.
Izdano: (2005) -
Novel therapeutic options for recurrent metastatic salivary gland tumors: Review of ongoing clinical trials
od: Avinash Pandey, et al.
Izdano: (2018-01-01) -
THERAPEUTIC OPTIONS FOR INVASIVE BREAST CANCER
od: Ganusevich O. N., et al.
Izdano: (2019-05-01)